MicroRNA-133b Dysregulation in a Mouse Model of Cervical Contusion Injury

Int J Mol Sci. 2024 Mar 6;25(5):3058. doi: 10.3390/ijms25053058.

Abstract

Our previous research studies have demonstrated the role of microRNA133b (miR133b) in healing the contused spinal cord when administered either intranasally or intravenously 24 h following an injury. While our data showed beneficial effects of exogenous miR133b delivered within hours of a spinal cord injury (SCI), the kinetics of endogenous miR133b levels in the contused spinal cord and rostral/caudal segments of the injury were not fully investigated. In this study, we examined the miR133b dysregulation in a mouse model of moderate unilateral contusion injury at the fifth cervical (C5) level. Between 30 min and 7 days post-injury, mice were euthanized and tissues were collected from different areas of the spinal cord, ipsilateral and contralateral prefrontal motor cortices, and off-targets such as lung and spleen. The endogenous level of miR133b was determined by RT-qPCR. We found that after SCI, (a) most changes in miR133b level were restricted to the injured area with very limited alterations in the rostral and caudal parts relative to the injury site, (b) acute changes in the endogenous levels were predominantly specific to the lesion site with delayed miR133b changes in the motor cortex, and (c) ipsilateral and contralateral hemispheres responded differently to unilateral SCI. Our results suggest that the therapeutic window for exogenous miR133b therapy begins earlier than 24 h post-injury and potentially lasts longer than 7 days.

Keywords: cervical spine; microRNA133b; motor cortex; scar tissue; spinal cord injury; spine trauma.

MeSH terms

  • Animals
  • Cervical Cord* / injuries
  • Contusions* / metabolism
  • Disease Models, Animal
  • Mice
  • MicroRNAs* / metabolism
  • MicroRNAs* / therapeutic use
  • Spinal Cord Injuries* / metabolism
  • Spinal Cord Injuries* / therapy

Substances

  • MicroRNAs
  • Mirn133 microRNA, mouse

Grants and funding

This research was supported by funding provided by NeOnc Technologies, Inc. (Los Angeles, CA, USA). The APC was funded by NeOnc Technologies, Inc. (Los Angeles, CA, USA).